Therapeutic antibodies for autoimmunity and inflammation (Q37736260)

22 August 2017

1 reference

title

Therapeutic antibodies for autoimmunity and inflammation (English)

1 reference

22 August 2017

0 references

1 reference

Andrew C Chan

1

1 reference

22 August 2017

Paul J Carter

series ordinal

2

1 reference

22 August 2017

publication date

1 May 2010

1 reference

Nature Reviews Immunology

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

301-316

1 reference

mAbs: a business perspective

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Continuous cultures of fused cells secreting antibody of predefined specificity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Monoclonal antibodies as innovative therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Fully human antibodies from transgenic mouse and phage display platforms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Human antibody libraries: a race to engineer and explore a larger diversity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

An integrated science-based approach to drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Industrialization of mAb production technology: the bioprocessing industry at a crossroads

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Potent antibody therapeutics by design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Engineered therapeutic antibodies with improved effector functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Molecular engineering and design of therapeutic antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Certolizumab pegol for the treatment of Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Maintenance therapy with certolizumab pegol for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Blockade of CD11a by Efalizumab in Psoriasis Patients Induces a Unique State of T-Cell Hyporesponsiveness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Omalizumab-induced reductions in mast cell Fce psilon RI expression and function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Omalizumab treatment downregulates dendritic cell FcepsilonRI expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Endocytosis, recycling, and degradation of unoccupied FcepsilonRI in human basophils

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Basophil phenotypes in chronic idiopathic urticaria in relation to disease activity and autoantibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Comparative studies of functional and binding assays for IgG anti-Fc(epsilon)RIalpha (alpha-subunit) in chronic urticaria.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Complement activation determines the therapeutic activity of rituximab in vivo.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Ten years of Orthoclone OKT3 (muromonab-CD3): a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Anti-CD3 antibodies: towards clinical antigen-specific immunomodulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Development trends for therapeutic antibody fragments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

When binding is enough: nonactivating antibody formats.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of acute renal allograft rejection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Isotype selection in antibody engineering

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Antibody therapeutics: isotype and glycoform selection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Engineered antibody Fc variants with enhanced effector function

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Glycosylation as a strategy to improve antibody-based therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Optimization of humanized IgGs in glycoengineered Pichia pastoris.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Engineered antibodies with increased activity to recruit complement

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Modulation of the effector functions of a human IgG1 through engineering of its hinge region

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Antibody pharmacokinetics and pharmacodynamics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

FcRn: the neonatal Fc receptor comes of age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Metabolic properties of IgG subclasses in man

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Increasing the serum persistence of an IgG fragment by random mutagenesis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Engineered human IgG antibodies with longer serum half-lives in primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

An engineered human IgG1 antibody with longer serum half-life.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Structural characterization of a human Fc fragment engineered for extended serum half-life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Enhanced antibody half-life improves in vivo activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Therapeutic antibody fragments with prolonged in vivo half-lives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

The impact of PEGylation on biological therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Designing CD4 immunoadhesins for AIDS therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Albumin binding as a general strategy for improving the pharmacokinetics of proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Retargeting serum immunoglobulin with bispecific diabodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Enhancement of therapeutic protein in vivo activities through glycoengineering

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Antibody-drug conjugates for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Bispecific T-cell engaging antibodies for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Recombinant approaches to IgG-like bispecific antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Quantitative Estimation of the Hybridization of Rabbit Antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Recombinant bispecific antibodies for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Hybrid antibodies can target sites for attack by T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Tumor regression in cancer patients by very low doses of a T cell-engaging antibody

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Treatment with a novel poly(ADP-ribose) glycohydrolase inhibitor reduces development of septic shock-like syndrome induced by zymosan in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

IL-1, IL-18, and IL-33 families of cytokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Development and function of TH17 cells in health and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Engineering of stable bispecific antibodies targeting IL-17A and IL-23.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Design and production of novel tetravalent bispecific antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Engineering bispecific antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Single-chain antigen-binding proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

"Diabodies": small bivalent and bispecific antibody fragments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Single-domain antibodies as building blocks for novel therapeutics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Hybrid hybridomas and their use in immunohistochemistry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Bispecific monoclonal antibodies from hybrid hybridomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

An efficient route to human bispecific IgG.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Antibody engineering to develop new antirheumatic therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Structural characterization of a human Fc fragment engineered for lack of effector functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Monoclonal antibodies: versatile platforms for cancer immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRI2761

Bispecific antibodies for cancer therapy

31 March 2020

1 reference

https://pubmed.ncbi.nlm.nih.gov/20414204

12 December 2020

Consensus statement regarding OKT3-induced cytokine-release syndrome and human antimouse antibodies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20414204

12 December 2020

Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20414204

12 December 2020

Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20414204

12 December 2020

Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20414204

12 December 2020

Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/20414204

12 December 2020

Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20414204

12 December 2020

A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/20414204

12 December 2020

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20414204

12 December 2020

Humanization of antibodies.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20414204

12 December 2020

Engineered anti-CD20 antibodies with enhanced complement-activating capacity mediate potent anti-lymphoma activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20414204

12 December 2020

Identifiers

DOI

10.1038/NRI2761

1 reference

22 August 2017

1 reference